Pulmatrix (NSDQ:PULM) said today that all dosing and follow-up visits have finished for its first-in-human study of an inhaled formulation of itraconazole as a treatment of allergic bronchopulmonary aspergillosis in people with asthma.
The inhaled iSperse formulation, called Pulmazole, was well-tolerated, according to the Lexington, Mass.-based company. Pulmatrix plans to launch a Phase II trial of its ABPA therapy in the fourth quarter this year.
Get the full story at our sister site, Drug Delivery Business News.
The post Pulmatrix touts data from first-in-human trial of inhaled anti-fungal therapy appeared first on MassDevice.